For research use only. Not for therapeutic Use.
SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA[1].
SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes[1].
SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993[1].
SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge[1].
| Catalog Number | I045517 |
| CAS Number | 2073059-82-0 |
| Synonyms | N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-4-[(2-morpholin-4-yl-2-oxoethyl)amino]benzamide |
| Molecular Formula | C23H24N4O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H24N4O4S/c1-30-19-8-4-16(5-9-19)20-15-32-23(25-20)26-22(29)17-2-6-18(7-3-17)24-14-21(28)27-10-12-31-13-11-27/h2-9,15,24H,10-14H2,1H3,(H,25,26,29) |
| InChIKey | BMMQYFWEGRLMNT-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)NCC(=O)N4CCOCC4 |
| Reference | [1]. Byungyong Ahn, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. |
